NCT04316117: Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

NCT04316117
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Bone
Additional Notes: Patients must be planning to receive either 1) chemotherapy, 2) HER2-targeted therapy or 3) 1st or 2nd line endocrine therapy for metastatic breast cancer
Exclusions: Patients who have received greater than 3 lines of cytotoxic chemotherapy for metastatic breast cancer; Patients with active unstable central nervous system (CNS) metastases or leptomeningeal carcinomatous
https://ClinicalTrials.gov/show/NCT04316117

Comments are closed.

Up ↑